SPTLC2-driven sphingolipid reprogramming of neutrophils impairs anti-tumour immunity and drives liver cancer progression
28 September 2026 at 08:00
Oncogene, Published online: 28 September 2026; doi:10.1038/s41388-026-03996-2
SPTLC2-driven sphingolipid reprogramming of neutrophils impairs anti-tumour immunity and drives liver cancer progression